Public Health Genomics: Chances and Challenges for the Future of Population Health
Expectations are high that genomics will soon contribute to the improvement of population health. The forum discussed chances and ethical, legal, social and polical challenges of the integration of genome-based knowledge and technologies into public health approaches from different stakeholders’ perspectives.
The report can be found here.
Thursday 4th October 2007, 14:30-18:30
Public Health in the Age of Genomics
What role for public health in the era of genomic medicine?
M Gwinn, Associate Director, National Office for Public Health Genomics,CDC, USA
Will genomics revolutionize public health?
W Ricciardi, Director, Institute of Hygiene, Faculty of Medicine, Catholic University of Sacred Heart, Italy
Fears and hopes of patients facing the rapid biotechnological progress
A Kent, Director, Genetic Interest Group, UK
Public health and genomics – a dangerous combination?
L Koch, Head of Department, Institute of Public Health, University of Copenhagen, Denmark
Ethical, legal and social aspects of biobanking and public health genomics
B Knoppers, Canada Research Chair in Law and Medicine, Faculté de droit, Université de Montréal, Canada
Why is public health genomics a priority for the European Commission?
K Freese, DG SANCO, European Commission, Luxembourg
Friday, 5th October 2007, 9:00-11:00
Public Health Genomics in Europe
What are the aims and objectives of the “Public Health Genomics
European Network (PHGEN)”?
A Brand, Director, German Centre for Public Health Genomics, Germany
Perspectives from human genetics for public health in Europe
JJ Cassiman, Director, Centre for Human Genetics, Catholic University Leuven, Belgium
Global and European issues in genetic test evaluation and regulation
R Zimmern, Director, Public Health Genomics Foundation, UK
Ensuring the promotion of public health is at the core of a developing bioeconomy
I Gillespie, Division Head, OECD
PHGEN I ended in March 2009. PHGEN II continued at Maastricht University and was led by Prof. Dr. Angela Brand. PHGEN II has officially ended on 30 November 2012 with the reporting period ending on 30 January 2013.
Follow us on TWITTER!
PHGEN II as a Success Story, Biobanks and Personalized Medicine
PHGEN II has been selected as one of the success stories funded by the EU heath programs. The detailed report can be found here. PHGEN II has also been mentioned in the report of the European Commission expert group on biobanks and can be found here. Further our project has been pubished in the European Science Foundation's 'Personalised Medicine for the European Citizen' and can be found here.
Meeting of European Alliance for Personalised Medicine
Commissioner Dalli (speech) and Cyprus Minister Mavroyiannis launched in Brussels on 18 September 2012 the manifesto by the newly-formed European Alliance for Personalised Medicine (EAPM), which brings together patient groups, academia, health professionals and industry, as well as the European Commission and the European Medicines Agency. This news has been covered by APM Health and the European Parliament Magazine. Click here for the picture of our PHGEN coordinator discussing with Commissioner Dalli.
During the final meeting in April 2012 in Rome, the PHGEN II European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies have been officially endorsed as the "Declaration of Rome 2012" by the European Member States as well as European key Institutions and Organizations such as EMA. The "Declaration of Rome 2012" has been published in the Journal "Drug Metabolism and Drug Interactions". It can be downloaded for free at the journal website here. Also a related editorial has also been published in the same journal which can be found at the journal website here. The "Declaration of Rome 2012" is the summary of the European Best Practice Guidelines for Quality Assurance, Provision and Use of Genome-based Information and Technologies produced in the form of 3 individual reports (QA, Provision & Use) by the PHGEN II consortium. These 3 parts can be accees below:
PHGEN II Extension Granted
Given the success of the project and realizing the deliverables go beyond the current deliverables, the PHGEN II project has been granted a 6 months cost netural extension by the EAHC. Therefore, the project will continue till the 30 November 2012. Originally the project was till 30 May 2012.
PHGEN II Final Meeting Rome
The PHGEN II final meeting (endorsement panel) took place in Rome, Italy. It was a success. Further information can be found here.
PHGEN II has released the definitions list which will be used as the guiding tools for the development of the guidelines. These constitute definitions developed during PHGEN I as well as new definitions. This can be found by clicking the link here.
The 3rd and final Steering Committee Meeting of PHGEN II took place on 23 February 2012 in Maastricht, The Netherlands. Further information can be found here.
ITFoM is one of six pilot projects in the European Future and Emerging Technologies Flagship scheme. These projects are vying for €1 billion funding from both the European Commission, Member States and other sources over ten years in order to generate a scientific revolution. Further information can be found from here.
Old information and news of PHGEN II can be found in the Archives here.
Public Health Genomics Journal
(Journal published in collaboration with GRaPH-Int)
'Public Health Genomics' is the first peer-reviewed international journal to focus on the translation of genome-based knowledge and technologies into public policy, disease prevention and the improvement of population health. It is a multidisciplinary bi-monthly forum containing conceptual and original research articles, editorials, reviews, short communications, country reports, case studies, viewpoints, news and various other features about the nature of public health genomics and related concepts.
For more details please visit http://www.karger.com/phg
PHGEN II is currently also developing a Wiki. This can be accessed here.
PHGEN II is coordinated by the Institute for Public Health Genomics (IPHG) at Maastricht University. The publication list contributed by partners of PHGEN II can be found here.
The IPHG coordinated the bachelor's program Public Health Genomics. The output of the successful course was a report made by the students with supervision from their supervisors. The report can be found here.
PHGEN II events have now officially ended.